Advanced gene delivery system secures Japan patent

ProBioGen has announced that the Japan Patent Office (JPO) has granted the first patent for the company’s DirectedLuck® technology. This advanced gene delivery system is anchored in a highly potent transposase fusion variant, facilitating epigenetic targeting alongside a meticulously designed transposon.

Dr Volker Sandig, Chief Scientific Officer of ProBioGen, emphasised the significance of this patent grant for the ground-breaking cell-engineering technology. The plug-and-play system offers advantages throughout the biopharmaceutical value chain, enabling accelerated timelines for clinical applications. Dr Sandig stated: ‘‘Thanks to our DirectedLuck® technology, clients attain higher titres and maximum stability within condensed timelines.’’

ProBioGen has successfully implemented DirectedLuck® to generate numerous producer cell lines for clients, garnering endorsement from ProBioGen’s licensees. Beyond its application in generating producer cell lines, DirectedLuck® proves versatile for creating stable packaging cell lines for viral vectors and finds utility in gene and cell therapy.

More information online